The longevity industry — startups trying to make people live longer or even forever, basically — tends to attract charlatans and scandal.

But a terrific feature story in New Statesman makes the case that a handful of ventures in the space are finally starting to hone in on some compelling ideas that might eventually provide modest or even radical life extension.

“I’m confident we’ll have an aging drug by the time it’s relevant for me,” 27-year-old Celine Halioua, a PhD dropout who now works at the anti-aging startup Loyal, who predicted that such a drug could become available “within a decade.”